RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability

INTRODUCTION: RELAY was a global, double-blind, placebo-controlled phase III study that demonstrated superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus placebo plus erlotinib (PBO + ERL) in the first-line treatment of patients with epidermal growth factor rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadal, Ernest, Horinouchi, Hidehito, Shih, Jin-Yuan, Nakagawa, Kazuhiko, Reck, Martin, Garon, Edward B., Wei, Yu-Feng, Kollmeier, Jens, Frimodt-Moller, Bente, Barrett, Emily, Lipkovich, Olga, Visseren-Grul, Carla, Novello, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763844/
https://www.ncbi.nlm.nih.gov/pubmed/34928484
http://dx.doi.org/10.1007/s40264-021-01127-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763844/
https://www.ncbi.nlm.nih.gov/pubmed/34928484
http://dx.doi.org/10.1007/s40264-021-01127-2

Ejemplares similares